Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fear & Greed Index
39 (Fear)
BUY WHEN UGLY
Shorts and MMs tried to get it below .265 now it’s time to SCRAAAMBLE!!!
25 and 50 SMA trying to catch up to 200 on 6 months chart
$.265 3 days it won’t go below that’s it’s tried THREE TIMES NOW
At 2024-05-08 09:30:04, there were 25,000 shares available with a fee of 50.54%.
The following is what happens ALL the time in the stock market, its what makes the charts we look at again
quite predictable other than being tough to accurately judge/predict the prices things peak or bottom out at.
The part that could get interesting is, suspect many held onto their shares hoping:
a. it would keep going, the momentum hasn't been stopped
b. if that didn't happen, pause, but no sell off
c. If a sell off happened, that it wouldn't be very deep
d. shares will look cheap now, don't worry the buyers will step in
But then something happens and the next phase called CONSOLIDATION kicks in:
e. a didn't happen
f. b did happen, but thats to be expected as holders, buyers and sellers wait to see what happens next
g. c did happen, momentum was broken, new buyers weren't present, and some holders started to decide to take profits
h. d did happen, there was 'nibbling' on the 'cheap' shares relative to the price it recently peaked at, but not enough to restore
the momentum.
i. and now with the slipping price, the loss of gains, the profit taking or in some cases, those caught chasing LATE
and paying more than than say 30 cents, start to realize losses
j. and the sell off gets a little more serious and has the POTENTIAL to get nasty UNLESS something is said
to stimulate a new round of buying.. because each drop in price, has the potential to turn another holder into a seller
k. this is the consolidation phase that shakes out a lot of the non-believers, the momentum traders.
the only question now is, where does it 'stop at' and we won't know that till it does for its own set of reasons.
Is your analysis saying buy it
Thanks. Years of charting or as they said in a course I took from IBD many years ago,
CHART PATTERNS REPEAT BECAUSE HUMANS ARE CREATURES OF HABIT
And many tend to do the same thing over and over again, especially when they are trained
to act the same way.
Its taking advantage of this knowledge that gives one the POTENTIAL to benefit from it..
(few guarantees in life, but...which is why I hedge my bets and don't say it WILL happen (smile)
I’m seeing a sea of Red today.. one more day of shaking the tree and two days of recovery this week… uhhhhhhh
I really love posts like this
Well now.. mentioned the share price and its MA line are going to want to get 'together' at some point.
When I first said it, the share price was around 32 cents, MA around 21 cents. Also mentioned the MA was in a nice uptrend
could play catch up more than the SP dropped. So far, playing out like that. Tho I sold cause I wasn't sure what was going to happen.
And a drop to 21 cents would have been a heck of a nice reload price..
But fast forward 2 days and the SP has dropped around 7%, but the MA line has not slowed down is now approaching 25 cents..
So looking like the MA is coming up to meet and greet its 'missing' friend the share price...
A little humor..
So how much 'crap' will JAGX have to 'deal with' in order to be profitable??
Sorry, but get some goofy thoughts at 6 in the morn when that first cup of coffee hasn't kicked in yet..
So it hit 40s today?....Down %6 is not down?....I wish it hit 40s ...But it didn't.. Dream worlds can be dangerous... maybe 40s this week,we shall see
Nice article today
Trading currently at 27 cents and with a market cap of $74 million, Jaguar Health (NASDAQ:JAGX) sits firmly inside the penny stock category. The company’s name gives a clue as to its mission, which is to use chemical derivatives from natural sources found in rainforests to develop novel pharmaceuticals.
These proprietary prescription medications are directed towards both people and animals with gastrointestinal issues such as an overactive bowel. Currently, one of the company’s subsidiaries, Napo Pharmaceuticals, is working to develop and commercialize a drug named crofelemer. This drug aims to treat chemotherapy-induced overactive bowel, which is a common symptom for many cancer patients.
With the drug currently in Phase 3 clinical trials, the potential for a spike in JAGX’s value is real. Though it will likely be a few more years, should the drug achieve regulatory approval, it could become a staple among chemotherapy treatments for symptom prevention. Pair this with aging populations around the developed world, and the demand for crofelemer could drive JAGX up even further
https://investorplace.com/2024/05/want-10000-invest-1000-in-these-3-penny-stocks-now/
Well that was the HUGE SCRE DROP DAY LOL NICE!!! Going .36+ this week!
Looks like we’re leveling off for the day. We’ll see what happens at power hour if it pops.
I will repeat myself, the SVP President international of ImmunoGen sold the company to ABBVIE earlier this year for 10 BILLION dollar.
That same guy has joined Jaguar as PRESIDENT of Jaguar International !!! OPEN YOUR EYES
Anyone not seeing the potential of this stock, doesn't deserve to be in it when the party starts.
Please leave or short it !
another one of those decision points. VOLUME has really dried up, guess is, holders, buyers and sellers are looking to see who moves 'first'..
I'm sure this is sykes and crew making their final exit.
Everyone is waiting for their results on Phase III trial for cancer therapy related diarrhea in humans (CTD): https://jaguar.health/pipeline/
Results should be out any day now, deadline is June, i think.
Name of the game I guess lol dead cat bounce we are not
chemo, but when? Is there enough to keep it going right now?
Damn if this isn’t a FU from buyers I don’t know what is!!! AWESOME recovery!
as is the 'norm' when the pullback first commences, 'some' see the shares as 'on discount/cheap'
and start nibbling..
Course, one never knows where it will land at till it does, so sometimes catching the 'falling knife' does work out..
Good luck..
disclaimer: just watching. Using 32-33 cents now as a 'target price' on the upside, tho I had thought 50 cents was possible
if they had released the PH 3 data while the momentum was high.
have to see where it bottoms out at and whether or not its worth grabbing another round of shares:
28 cents to 32 cents would be a 15% return... for example..
There's bigger catalyst here to make this Solidify.
Is dog diarrhea approval the catalyst here or something bigger coming, and when?
Love watching my position go down $2000 then right back up lol
Exactly hitting all the stop losses!!! Love hate this kinda play from them !!! Uhhh
MM’s are killing pps today. Evil bastards. Someone wants to buy a boat load cheap I think.
Just needs to stay above .26 below game over….
as fast as its run up, ya have to figure, those that jumped on board trying to get some, will leave just as fast once they realize the
party is over for the moment.
I use the Moving Average line as a 'target' for the share price to bounce of on a pullback. Its down around 23 cents this morn (up from 21 cents' the other
day).
As always, the best we can do is 'guess' and then see what happens, and if we are so inclined, be ready to take advantage of it.. (buying opportunity)..
Unfortunately, as essentially a penny stock, no real institutional support at this price level?? It could get just as nasty as it did 'good'..
Gonna be ugly today MMs going to shake the TREE!!!
Any opinions on this : The new president of Jaguar International , was (co-) responsible for the biggest buy out deal of 2023. They sold ImmunoGEN for 10 BILLION dollars to ABBVIE, after that ImmunoGen reported positive phase 3 data in May 2023, earlier that year.
Seems like that guy seems a similar opportunity with Jaguar Health? Maybe not in buy out deal, but in a partnership deal?
Don't think so ... already has gone up a bit....Flat to Down probably
Prescription drug could prevent cancer therapy-related diarrhoea
Stomach pain
30 January 2024
Posted in Cancer Research, News | Tagged Cancer treatment, Chemotherapy, Napo Pharmaceuticals, Oncology, Preclinical investigations, Puma Biotechnology
A study in dogs has shown that crofelemer can provide symptomatic relief of diarrhoea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) neratinib (Nerlynx).
Puma Biotechnology’s Nerlynx is a pan HER TKI indicated for the extended adjuvant treatment of adult patients with early stage and metastatic HER2 positive breast cancer.
The study was conducted by Jaguar company Napo Pharmaceuticals in collaboration with Puma Biotechnology.
Cancer therapy-related diarrhoea (CTD) has the potential to cause dehydration, infections and non-adherence to treatment, and is a growing unmet medical need in cancer patients.
“We are very pleased with the results of this prophylactic study, which was undertaken to ‘model’ the human situation with neratinib,” said Lisa Conte, Jaguar’s President and CEO. “Crofelemer, our novel, oral, plant-based, non-opioid antidiarrhoeal prescription medication, is also the subject of OnTarget, Jaguar’s pivotal Phase III clinical trial for the follow-on indication of the preventative treatment of CTD, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB).”
Dr Michael Guy, Jaguar’s Vice President of Preclinical and Nonclinical Studies, added: “The study demonstrated that crofelemer caused an approximate 30% reduction in the incidence and severity of diarrhoea associated with daily oral administration of neratinib, which was statistically significant.”
In a pilot Phase II study in humans, seven patients underwent treatment with crofelemer and loperamide, five of whom were able to control diarrhoea with crofelemer alone.
“Though this study involved a small number of patients, the results show activity of crofelemer for the management of neratinib-induced diarrhea, which warrants further investigation of crofelemer for treatment of cancer therapy-related diarrhea (CTD),” said study investigator Hope Rugo, Professor of Medicine and Winterhof Family Professor of Breast Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Followers
|
155
|
Posters
|
|
Posts (Today)
|
9
|
Posts (Total)
|
6659
|
Created
|
12/01/15
|
Type
|
Free
|
Moderators ProfitChaser oldstocks DTGoody powerbattles crudeoil24 SmellMyFinger |
Jaguar Health, Inc. $JAGX
Bringing Plant-based Medicines to Life™
Pharmaceutical Manufacturing
San Francisco, California
Jaguar Health’s organizational framework is designed to enable our product pipeline to reach the world’s interconnected marketplace, allowing for development and commercialization opportunities worldwide.
Products:
Mytesi Crofelemer 125mg delayed release tablets
Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Market size of the FDA HIV Mytesi Crofelemer could be $25-$30 Million in the USA
Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea.
Mytesi is not indicated for the treatment of infectious diarrhea. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).
Canalevia-CA1 Crofelemer delayed release tablets
Distributors listed:
https://www.canalevia.com/distributor-information
CANALEVIA-CA1 is conditionally approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.
Lytham Partners Investor Select Conference February 1st, 2024
https://wsw.com/webcast/lytham10/jagx/2084640
Pipeline: https://jaguar.health/pipeline/
How to calculate the value of drugs and biotech companies
https://www.baybridgebio.com/drug_valuation.html
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy.
Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study , a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative is focused on developing novel prescription medicines derived from plants for mental health indications.
A Case Report: Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea
Despite the efficacy of tyrosine kinase inhibitors (TKIs) across multiple cancers, side effects including treatment-related diarrhea can impede a patient’s ability to reach therapeutic doses or stay on therapy.
Below, we present the case of a 72-year-old patient with metastatic papillary renal cell carcinoma recurrent despite nephrectomy.
Over the course of treatment, the patient received multiple different tyrosine kinase inhibitors with varying efficacy.
Treatment with the TKI cabozantinib after failure of two prior TKIs resulted in a clinical response with shrinkage of his nodal metastatic disease.
However, the severe treatment-related diarrhea refractory to conventional management required both dose holds and dose reductions of cabozantinib.
Off-label administration of crofelemer, a novel FDA-approved antidiarrheal agent, successfully controlled the treatment-related diarrhea and allowed resumption and partial dose increase of cabozantinib.
This case suggests that crofelemer could be a viable therapeutic strategy to address TKI-induced diarrhea.
9.8 million people
receive chemotherapy worldwide per year
Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9
Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients
Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164
Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD
Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111
Research & Development
In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial
This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy
The principal investigator and co-investigators identified are from MD Anderson Cancer Center
Jaguar Health https://jaguar.health/
Napo Pharmaceuticals https://napopharma.com/
Napo Therapeutics https://napotherapeutics.com/en/
https://www.magdalenabiosciences.com/
Magdalena is a joint venture formed by Jaguar Health and Filament Health. The company holds an exclusive license to Jaguar's proprietary library of approximately 2,300 highly characterized medicinal plants and 3,500 plant extracts for designated therapeutic indications.
Visit Jaguar on LinkedIn:
https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Phone: 415-371-8300
Contact: hello@jaguar.health
Press Releases: https://jaguarhealth.gcs-web.com/news-releases
Most if not all works by mechanism chloride ions into the gut then water comes and diarrhea out. Crofelemer normalizes abnormal ion flow targeting only locally in the gut.
Jaguar has been putting the expense into making sure Crofelemer drug supply is ready to get into this opportunity to treat cancer related chemo patients since pharmacy’s already can get FDA approved, all ready in the in the supply chain in the pharmacy as Crofelemer for AIDs patients.
Research has shown it costs 3x as much to treat a cancer patient with diarrhea.
It would be better to treat the cancer patient for diarrhea with Crofelemer pending OnTarget Study and FDA approval.
Since Crofelemer is FDA approved to treat dogs for Cancer Chemo related Diarrhea it has been said:
If your going to have cancer and cancer related Diarrhea, it’s better to be a dog than a human right now.
The companies that manufacture the cancer agents/drugs sort of point to the availability of Crofelemer because it allows them to keep their patients on their therapies thereby improving their penetration and their revenues opportunity.
3rd party market research put Short Bowel Syndrome at $5-$12 Billion opportunity because these patience are so ill, high mortality, high morbidity (the state of being unhealth for a particular disease or situation), so high of expense to manage through life.
That opportunity can be reached in small trials around the world to show benefits to be able to show global development.
Product already approved, already fully in the supply chain in the pharmacy.
Potential Market of Mytesi (crofelemer)
Jaguar and Napo $JAGX if the Phase 3 OnTarget Study has good results.
The Phase 3 OnTarget Study results are due to be out soon in this quarter.
The Phase 3 OnTarget study is testing whether the company's plant-based prescription drug crofelemer can prevent or substantially reduce diarrhea and other symptoms of CIOB when any one of the selected 24 different targeted therapies that are associated with diarrhea in patients is initiated.
Each year, more than 1 million cancer patients in the United States receive chemotherapy or radiation. Globally 9.8 million require chemotherapy.
Diarrhea is a common side effect of targeted therapies. Up to 95% of patients on tyrosine kinase inhibitors (TKIs) suffer from diarrhea, depending on the TKI used.
Any drug used to treat cancer (including tyrosine kinase inhibitors or TKIs) can be considered chemo, but here chemo is used to mean treatment with conventional cytotoxic (cell-killing) drugs that mainly kill cells that are growing and dividing rapidly. Chemo was once one of the main treatments for CML.
The cost for Mytesi oral delayed release tablet 125 mg is around $2,600 for a supply of 60 tablets. This amount is the one month supply as testing in the OnTarget Study.
That is a 24 week study = 5.6 month supply needed = $14,560.00 for treatment.
Potential Market of Mytesi (crofelemer)
100,000 patients a year = $1,456,000,000
250,000 patients a year = $3,640,000,000
500,000 patients a year = $7,280,000,000
1,000,000 patients a year = $14,560,000,000 (assuming worldwide)
5,000,000 patients a year = $72,800,000,000 (assuming worldwide)
The estimate of patients depends on how many quit taking chemo, the onTarget Study, FDA approval and or quit taking Mytesi (crofelemer).
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |